Compare SHLS & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHLS | NTLA |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2020 | 2016 |
| Metric | SHLS | NTLA |
|---|---|---|
| Price | $6.20 | $13.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 20 |
| Target Price | $9.21 | ★ $20.45 |
| AVG Volume (30 Days) | ★ 5.8M | 3.6M |
| Earning Date | 05-27-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | 27.43 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $475,331,000.00 | $67,671,000.00 |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $11.21 | $73.07 |
| P/E Ratio | $30.65 | ★ N/A |
| Revenue Growth | ★ 19.07 | 16.92 |
| 52 Week Low | $2.92 | $5.90 |
| 52 Week High | $11.36 | $28.24 |
| Indicator | SHLS | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 52.33 |
| Support Level | $5.49 | $10.44 |
| Resistance Level | $6.26 | $15.06 |
| Average True Range (ATR) | 0.43 | 0.96 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 35.11 | 29.56 |
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.